ALAS2 (5'-aminolevulinate synthase 2) is the erythroid-specific isoform of aminolevulinic acid synthase that catalyzes the first and rate-limiting step of heme biosynthesis in red blood cells. The enzyme performs pyridoxal 5'-phosphate (PLP)-dependent condensation of succinyl-CoA and glycine to form aminolevulinic acid (ALA), producing CoA and CO2 as by-products 1. ALAS2 exhibits 65-75% of the catalytic activity compared to the housekeeping ALAS1 isoform and localizes to the mitochondrial matrix 1. The enzyme plays a critical role in erythropoiesis and hemoglobin biosynthesis, making it essential for red blood cell development and maturation 2. ALAS2 dysfunction leads to two distinct X-linked blood disorders: loss-of-function mutations cause X-linked sideroblastic anemia characterized by ring sideroblast formation and impaired heme synthesis 34, while gain-of-function mutations result in X-linked dominant erythropoietic protoporphyria due to excess protoporphyrin accumulation 35. The gene serves as a biomarker for blood identification in forensic applications and shows upregulation during high-altitude acclimatization, reflecting increased erythropoiesis in hypoxic conditions 62. Clinical management focuses on monitoring hematological parameters and preventing disease progression.